- Tens of thousands of Indonesians rally over Trump's Jerusalem stance
- Second prototype of China's C919 jet conducts test flight: state TV
- North Korea threat on agenda when South Korean foreign minister visits
- Pentagon study of UFOs revealed
- Australia arrests man accused of trying to sell missile parts for Nort
- How Australia's PM went swimming 50 years ago and vanished forever
- Hundreds come down with stomach illness during Royal Caribbean cruise
- Australian police accuse man of acting as North Korean economic agent
- Hoping to extend maritime reach, China lavishes aid on Pakistan town
- Mudslide in southern Chile kills five, at least 15 missing
- Honduran helicopter crash kills six, including president's sister
- Brazil's Workers Party formalizes support for ex-president Lula
- Foreign minister warns UK cannot become 'vassal state' of EU
- More than half of Britons now want to stay in EU - poll
- An update on winners and losers on the U.S. tax scorecard
- Uber accused of espionage, hacking and bribery in bombshell letter
- Christian Bale and more to salute CNN Heroes
- Destiny 2 Xur Location Guide: Where Is Xur, What Is He Selling? (December 15-18)
- More than half of Britons now want to stay in EU: poll
- Mudslide in southern Chile kills three; 15 others missing
Sage's depression drug succeeds in mid-stage study, shares soar
(Reuters) - Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal of reducing symptoms in a mid-stage study, sending its shares soaring 52.3 percent in premarket trading.
The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, when compared to a placebo.
Depression is a common mental illness characterized by persistent sadness and a loss of interest and lack of ability to do everyday activities and work.
The drug was granted fast-track designation by the U.S. Food and Drug Administration in May, the company said.
Patients were assessed on a scale that rated the severity of their depression symptoms such as mood, feelings of guilt, suicidal thoughts and insomnia.
Sage’s postpartum depression drug succeeded in two late-stage studies in November, paving the way for it to bring to market the first FDA-approved treatment for the disorder.
The company’s shares jumped 52.3 percent to $140 in premarket trading.
Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta
Our Standards:The Thomson Reuters Trust Principles.